JIANZHIJIA PHARMACEUTICAL CHAIN GROUP CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 50.8 CNY | -2.66% |
|
-2.59% | -14.48% |
| 26/04 | Jianzhijia Pharmaceutical Chain Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 13/02 | JZJ Chain Drugstore Acquires 69 Pharmacies For 46 Million Yuan | MT |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Drug Retailers
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -14.48% | 929M | - | ||
| -31.33% | 11.31B | B | ||
| +13.51% | 6.47B | C | ||
| -30.66% | 6.32B | B | ||
| -8.33% | 6.09B | C+ | ||
| +74.00% | 4.95B | C | ||
| -1.61% | 4.67B | D- | ||
| -6.00% | 3.95B | B | ||
| -16.14% | 3.34B | C- | ||
| -12.02% | 2.92B | C- |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 605266 Stock
- Ratings Jianzhijia Pharmaceutical Chain Group Co., Ltd.
